$
Federal Contract Award
Locus Biosciences INC
Department of Health and Human Services · September 16, 2025 · FY2025
75A50120C00169Full & OpenNAICS 541714
Obligated
$73,885,104
Contract details
- Award ID
- CONT_AWD_75A50120C00169_7505_-NONE-_-NONE-
- PIID
- 75A50120C00169
- Period of performance
- September 28, 2020 → December 31, 2026
- Place of performance
- MORRISVILLE, NC, USA
- Set-aside
- None (Full & Open)
- Pricing type
- COST SHARING
- PSC
- AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- NAICS
- 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Scope
CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS
Parent vehicle (IDV)
Locus Biosciences INC
UEI CJKVLKZGX6F3
This award was placed as a task/delivery order under a larger contract vehicle.
Recipient
Locus Biosciences INC →- UEI
- CJKVLKZGX6F3
- CAGE
- 7H2T2
- Parent
- Locus Biosciences INC
- Address
- MORRISVILLE, NC
Awarding agency
Department of Health and Human Services →- Sub-agency
- Office of Assistant Secretary for Preparedness and Response
- Office
- BARDA - ASPR / DAAPPO / BARDA DCMA
- Funding agency
- Department of Health and Human Services
- Funding office
- BARDA - ASPR / DAAPPO / BARDA DCMA
See every contract Locus Biosciences INC has won
Full contracting history, year-over-year trends, subaward graph, and recompete alerts.
View Locus Biosciences INC profile →